ClinicalTrials.gg
CompletedNCT06605950Updated Jul 4, 2025

A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult Participants

A Phase 1 interventional study of KarXT and KarX-EC in Healthy Volunteers, sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company. Completed at 1 site in United States. Open to participants aged 19 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-04.

Sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2025, 1 year 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
19 Years to 90 Years
Sex
All
01

Study summary

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of multiple doses of KarXT + KarX-EC capsules versus KarXT capsules in healthy adult and elderly participants of Japanese ethnicity and to assess the effect of multiple doses of omeprazole on the exposure of xanomeline and trospium administered as KarXT + KarX-EC capsules in healthy adult participants.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Japanese
  • Elderly
  • Adult
  • Healthy
  • Pharmacokinetics
  • BMS-986510
  • BMS-986519
  • KarXT
  • Omeprazole
  • Drug interaction
03

In context

Lead sponsor

Karuna Therapeutics, Inc., a Bristol Myers Squibb company is the lead sponsor of 17 studies on the registry; 8 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.

First submitted after Karuna Therapeutics, Inc. became part of Bristol-Myers Squibb.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Inclusion Criteria for Healthy Adult Japanese Participants (Group A):.
  • Healthy adult participants must be 19 to 55 years of age, inclusive.

    i) Both participant's biological parents are of ethnic Japanese ancestry. Participants must be first generation Japanese.

ii) Must have a (BMI) of 18.0 to 32.0 kg/m2 (inclusive), at the time of signing the ICF.

iii) Must have an estimated (eGFR) of ≥ 90 mL/min/1.73m2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation at the screening visit. One repeat measurement is allowed.

  • Inclusion Criteria for Healthy Elderly Japanese Participants (Groups B and C):.
  • Healthy elderly participants must be 56 to 90 years of age, inclusive.

    i) Both participant's biological parents are of ethnic Japanese ancestry. Participants must be first generation Japanese.

ii) Must have a BMI ≥ 18.0 and ≤ 35.0 kg/m2 (inclusive), at the time of signing the ICF.

iii) Must have an eGFR of > 60 mL/min/1.73m2 by the CKD-EPI equation at the screening visit. One repeat measurement is allowed.

  • Inclusion Criteria for Healthy Adult Participants (Groups D):.
  • Healthy adult participants must be 19 to 55 years of age, inclusive.

    i) Participants with any ethnicity can be included.

ii) Must have a BMI of 18.0 to 32.0 kg/m2 (inclusive), at the time of signing the ICF.

iii) Must have an eGFR of ≥ 90 mL/min/1.73m2 by the CKD-EPI equation at the screening visit. One repeat measurement is allowed.

Exclusion criteria

Exclusion Criteria

- Exclusion Criteria for All Participants (Groups A, B, C, and D):.

i) Participant is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.

ii) History or presence of medical or psychiatric condition or disease in the opinion of the PI or designee.

iii) Participant has a history of syncope and/or symptomatic orthostatic hypotension in the year prior to Day 1.

iv) History of cancer that has not been in full remission for >5 years (except basal cell skin cancer or squamous cell skin cancer with history of curative treatment and no recurrence for > 1 year prior to the screening visit).

  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    Group A

    Drug: KarXT · Drug: Placebo

  • Experimental
    Group B

    Drug: KarXT · Drug: Placebo

  • Experimental
    Group C

    Drug: KarXT · Drug: KarX-EC · Drug: Placebo

  • Experimental
    Group D

    Drug: KarXT · Drug: KarX-EC · Drug: Omeprazole

Interventions

  • DrugKarXT

    Drug pages: Xanomeline · Trospium

    Specified dose on specified days

    Also known as: BMS-986510, Xanomeline/Trospium Chloride

  • Specified dose on specified days

    Also known as: BMS-986519, Xanomeline Enteric-coated

  • DrugPlacebo

    Specified dose on specified days

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Number of participants with Adverse Events (AEs)

    Part 1

    Time frame: Up to 28 days post last dose

  2. Number of participants with Serioues AEs (SAEs)

    Part 1

    Time frame: Up to 28 days post last dose

  3. Number of participants with vital sign abnormalities

    Part 1

    Time frame: Up to 28 days post last dose

  4. Body weight

    Part 1

    Time frame: Up to 28 days post last dose

  5. Number of participants with 12-lead electrocardiogram abnormalities

    Part 1

    Time frame: Up to 28 days post last dose

  6. Number of participants with physical examination abnormalities

    Part 1

    Time frame: Up to 28 days post last dose

  7. Number of participants with clinical laboratory assessment abnormalities

    Part 1

    Time frame: Up to 28 days post last dose

  8. Columbia-Suicide Severity Rating Scale (C-SSRS)

    Part 1

    Time frame: On Day 30

  9. Maximum observed plasma concentration (Cmax)

    Part 2

    Time frame: Up to Day 29

  10. Time of maximum observed plasma concentration (Tmax)

    Part 2

    Time frame: Up to Day 29

  11. Area under the concentration-time curve in 1 dosing interval (AUC(TAU))

    Part 2

    Time frame: Up to Day 29

  12. Area under the plasma concentration-time curve from time zero to 24 hours (AUC(0-24))

    Part 2

    Time frame: Up to Day 29

  13. Apparent total body clearance (CLT/F)

    Part 2

    Time frame: Up to Day 29

  14. Apparent volume of distribution (Vz/F)

    Part 2

    Time frame: Up to Day 29

  15. Terminal elimination half-life (T-HALF)

    Part 2

    Time frame: Up to Day 29

Secondary outcomes

  1. Cmax

    Part 1

    Time frame: Up to Day 29

  2. Tmax

    Part 1

    Time frame: Up to Day 29

  3. AUC(0-24)

    Part 1

    Time frame: Up to Day 29

  4. AUC(TAU)

    Part 1

    Time frame: Up to Day 29

  5. Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))

    Part 1

    Time frame: Up to Day 29

  6. CLT/F

    Part 1

    Time frame: Up to Day 29

  7. Vz/F

    Part 1

    Time frame: Up to Day 29

  8. T-HALF

    Part 1

    Time frame: Up to Day 29

  9. Number of participants with AEs

    Part 2

    Time frame: Up to 28 days post last dose

  10. Number of participants with SAEs

    Part 2

    Time frame: Up to 28 days post last dose

  11. Number of participants with vital sign abnormalities

    Part 2

    Time frame: Up to 28 days post last dose

  12. Body weight

    Part 2

    Time frame: Up to 28 days post last dose

  13. Number of participants with 12-lead electrocardiogram abnormalities

    Part 2

    Time frame: Up to 28 days post last dose

  14. Number of participants with physical examination abnormalities

    Part 2

    Time frame: Up to 28 days post last dose

  15. Number of participants with clinical laboratory assessment abnormalities

    Part 2

    Time frame: Up to 28 days post last dose

  16. C-SSRS

    Part 2

    Time frame: On Day 30

07

Study locations

1 site
  • Cenexel ACT (Anaheim Clinical Trials)
    Anaheim, California 92801, United States
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in May 2025, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2024
First posted
Sep 20, 2024
StartActual
Oct 1, 2024
Primary completionActual
May 31, 2025
CompletionActual
May 31, 2025
Last update
Jul 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06605950
Responsible party
Sponsor
First posted
Sep 20, 2024
Start date
Oct 1, 2024
Primary completion
May 31, 2025
Completion
May 31, 2025
Last update
Jul 4, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Xanomeline · Trospium · Omeprazole

Start the discussion